GlassScriptPhysician profile
Chetna Dengri
NPI 1326770942
$1,589.18
in general payments reported to CMS, 2019-2025
20 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.17 · 2023: $275 · 2024: $594 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $413.48 | 2023-2025 | Qulipta, Ubrelvy |
| Ucb, INC. | $252.71 | 2023-2025 | Fintepla, Rystiggo, Briviact |
| Alexion Pharmaceuticals, INC. | $204.69 | 2023-2025 | Ultomiris |
| Argenx US, INC. | $177.94 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $58.81 | 2023-2025 | Nuplazid, Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $54.52 | 2024-2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $54.36 | 2025 | Wainua |
| Neurelis, INC. | $49.75 | 2023-2025 | Valtoco |
| Boston Scientific Corporation | $47.17 | 2025 | Watchman Flx |
| Merz Pharmaceuticals, LLC | $36.02 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Livanova USA, INC. | $31.77 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mallinckrodt Hospital Products INC. | $29.76 | 2025 | Acthar |
| Tg Therapeutics, INC. | $29.62 | 2025 | |
| Eisai INC. | $27.24 | 2024 | |
| Amgen INC. | $25.32 | 2023 | Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $23.74 | 2024 | |
| Lundbeck LLC | $20.13 | 2024 | Vyepti |
| Novo Nordisk INC | $19.54 | 2023 | |
| Cycle Pharmaceuticals INC | $17.67 | 2025 | Bafiertam, Tascenso Odt |
| Neurocrine Biosciences, INC. | $14.94 | 2023 | Ingrezza, Ongentys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chetna Dengri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.